前列腺癌的生物标志物：当前的临床应用和未来展望。
Biomarkers in prostate cancer - Current clinical utility and future perspectives.
机构信息
The Vancouver Prostate Centre and Department of Urological Sciences, University of British Columbia, Vancouver, British Columbia, Canada; Department of Urology, Ludwig-Maximilians University Munich, Munich, Germany.
Martini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Hamburg, Germany; Department of Urology, University Hospital Hamburg-Eppendorf, Hamburg, Germany.
出版信息
Crit Rev Oncol Hematol. 2017 Dec;120:180-193. doi: 10.1016/j.critrevonc.2017.11.007. Epub 2017 Nov 13.
Current tendencies in the treatment course of prostate cancer patients increase the need for reliable biomarkers that help in decision-making in a challenging clinical setting. Within the last decade, several novel biomarkers have been introduced. In the following comprehensive review article, we focus on diagnostic (PHI, 4K score, SelectMDx, ConfirmMDx, PCA3, MiPS, ExoDX, mpMRI) and prognostic (OncotypeDX GPS, Prolaris, ProMark, DNA-ploidy, Decipher) biomarkers that are in widespread clinical use and are supported by evidence. Hereby, we focus on multiple clinical situations in which innovative biomarkers may guide decision-making in prostate cancer therapy. In addition, we describe novel liquid biopsy approaches (circulating tumor cells, cell-free DNA) that have been described as predictive biomarkers in metastatic castration-resistant prostate cancer and might support an individual patient-centred oncological approach in the nearer future.
当前前列腺癌患者治疗过程中的一些趋势增加了对可靠生物标志物的需求，这些标志物有助于在具有挑战性的临床环境中做出决策。在过去的十年中，已经引入了几种新型生物标志物。在以下的全面综述文章中，我们重点介绍了广泛应用于临床并得到证据支持的诊断（PHI、4K 评分、SelectMDx、ConfirmMDx、PCA3、MiPS、ExoDX、mpMRI）和预后（OncotypeDX GPS、Prolaris、ProMark、DNA 倍性、Decipher）生物标志物。在多种临床情况下，创新的生物标志物可能会指导前列腺癌治疗的决策。此外，我们还描述了新的液体活检方法（循环肿瘤细胞、游离 DNA），这些方法已被描述为转移性去势抵抗性前列腺癌的预测生物标志物，可能在不久的将来支持个体化的以患者为中心的肿瘤学方法。
Zotero 插件